The story
On June 8, 2006, the U.S. Food and Drug Administration approved Gardasil, made by Merck, the first vaccine against human papillomavirus (HPV), a very common sexually transmitted virus. The vaccine protects against four types, 16 and 18, which together cause about 70 percent of cervical cancers, and 6 and 11, which cause most genital warts. It was approved for girls and women aged 9 to 26, and in 2009 a second vaccine, Cervarix, was approved. Gardasil 9, approved in 2014, covers nine types. It was the first vaccine to prevent a cancer by blocking its viral cause.
The link between the virus and cancer was found by the German virologist Harald zur Hausen, who in the early 1980s identified DNA of HPV types 16 and 18 in cervical tumors, work that won the 2008 Nobel Prize in Physiology or Medicine. The vaccine's technology came from recombinant DNA: scientists including Ian Frazer and Jian Zhou in Australia, and Douglas Lowy and John Schiller in the United States, found that the virus's outer coat protein, called L1, assembles itself into empty shells called virus-like particles. These look like the virus but contain no DNA, so they cannot infect, and they trigger strong immunity. Manufacturers produce them in yeast or insect cells.
Cervical cancer kills about 350,000 women a year worldwide, mostly in countries without routine screening. Australia began a national school vaccination program in 2007, and many countries followed. Results have been dramatic: a Swedish study published in 2020 found 88 percent fewer cervical cancers among women vaccinated before age 17. Uptake has varied, and the vaccine has met hesitancy, though large studies have found it safe. The World Health Organization launched a plan in 2020 to eliminate cervical cancer as a public health problem and has since backed single-dose schedules to make vaccination easier.
Why it mattered
- Cervical cancer is on course to become the first cancer eliminated as a public health problem in countries with high vaccination and screening.
- Vaccination also lowers other HPV-related cancers, including some of the throat, anus and genitals, as well as genital warts.
- The virus-like-particle approach opened the way for other vaccines against viral diseases.
- Boys were later included in vaccination programs in many countries, to increase protection across the population.
Sources
- Gardasil Britannica
- HPV vaccine effective against cervical cancer Karolinska Institutet
- Human Papillomavirus (HPV) Vaccine National Cancer Institute
- The Nobel Prize in Physiology or Medicine 2008 - Popular information Nobel Prize
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…